https://orcid.org/0000-0002-1179-194X
Selected Grants
An Observational Study of Natural Disease Progression in Participants with Macular Dystrophies Expressing a Stargardt-type Clinical Presentation
Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Global Development, Inc · 2026 - 2031A Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene
Clinical TrialPrincipal Investigator · Awarded by Laboratoires Thea S.A.S. (Thea Laboratories) · 2025 - 2030Defining the underlying causes of retinal degeneration in CRB1 disease
ResearchCo Investigator · Awarded by Foundation Fighting Blindness, Inc · 2024 - 2029A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Tinlarebant in Japanese Subjects with Stargardt Disease and a Phase 2/3, Randomized, Double masked, and Placebo controlled Study to Evaluate
Clinical TrialPrincipal Investigator · Awarded by Belite Bio (HK) Limited · 2024 - 2029Gene-agnostic therapy for autosomal dominant retinitis pigmentosa
ResearchPrincipal Investigator · Awarded by Research To Prevent Blindness, Inc. · 2025 - 2029Medical Scientist Training Program
Inst. Training Prgm or CMEPreceptor · Awarded by National Institute of General Medical Sciences · 2022 - 2027Role of Proteasome Overload in Pathogenesis of Retinitis Pigmentosa
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2027Gene-Agnostic Therapy for Retinal Degenerations
ResearchCo Investigator · Awarded by Foundation Fighting Blindness, Inc · 2024 - 2027Development of gene supplementation therapy for PROM1-associated inherited retinal degenerations
ResearchPrincipal Investigator · Awarded by Retina Research Foundation · 2026 - 2026Development of Gene Supplementation Therapy for TULP1-Associated Hereditary Retinopathies
ResearchPrincipal Investigator · Awarded by VitreoRetinal Surgery Foundation · 2025 - 2026Investigating The Prevalence And Phenotypes Of PRPH2-Associated Maculopathies Among Patients Clinically Diagnosed With Age-Related Macular Degeneration
FellowshipPrincipal Investigator · Awarded by Research To Prevent Blindness, Inc. · 2025 - 2026A Phase Ib, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered DF-003 in ROSAH Syndrome Patients
Clinical TrialPrincipal Investigator · Awarded by Shanghai Yao Yuan Biotechnology, Ltd _ AKA Drug Farm · 2025 - 2026Development of gene supplementation therapy for PROM1-associated inherited retinal degenerations
ResearchPrincipal Investigator · Awarded by Retina Research Foundation · 2025 - 2025Development of gene supplementation therapy for PROM1-related inherited retinal degenerations
ResearchPrincipal Investigator · Awarded by VitreoRetinal Surgery Foundation · 2024 - 2025Vitamin A Supplementation to Alleviate Night Vision Impairment in Choroideremia Patients
ResearchPI-Fellow · Awarded by Foundation Fighting Blindness, Inc · 2021 - 2024External Relationships
- Astellas Pharma Inc.
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.